BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/23/2021 2:14:14 PM | Browse: 457 | Download: 1728
 |
Received |
|
2021-04-22 20:53 |
|
Peer-Review Started |
|
2021-04-22 20:56 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-05-24 01:19 |
|
Revised |
|
2021-06-04 19:17 |
|
Second Decision |
|
2021-07-02 13:05 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-07-02 13:39 |
|
Articles in Press |
|
2021-07-02 13:39 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-11-17 16:02 |
|
Typeset the Manuscript |
|
2021-12-07 02:26 |
|
Publish the Manuscript Online |
|
2021-12-23 14:14 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jose María Huguet, Xavier Cortés, Marta Maia Bosca-Watts, Marian Aguas, Nuria Maroto, Lidia Martí, Cirilo Amorós and Jose María Paredes |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jose María Huguet, MD, Reader (Associate Professor), Department of Gastroenterology, General University Hospital of Valencia, Av Tres cruces, Valencia 46014, Spain. josemahuguet@gmail.com |
| Key Words |
Crohn’s disease; Ulcerative colitis; Inflammatory bowel disease; Infliximab; Biosimilar; CT-P13 |
| Core Tip |
In this work, we have analyzed the effectiveness and safety of the infliximab biosimilar CT-P13 in the treatment of inflammatory bowel disease (IBD) in real-life practice. Our results show that CT-P13 is an effective and safe biosimilar of infliximab, being a valid and attractive alternative for the treatment of IBD since it allows for a reduction of healthcare costs and facilitates access to biological treatments for more patients. |
| Publish Date |
2021-12-23 14:14 |
| Citation |
Huguet JM, Cortés X, Bosca-Watts MM, Aguas M, Maroto N, Martí L, Amorós C, Paredes JM. Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease. World J Clin Cases 2021; 9(36): 11285-11299 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i36/11285.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i36.11285 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
